中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu

2022 No.6
Theme Issue: Advances and Challenges in Cirrhotis Portal Hypertension
Executive Chief Editor: CHEN Jinjun  
Nanfang Hospital of Southern Medical University
Cover Content

 Previous Issue | Next Issue 

Display Method:
Editorial
Advances and challenges in cirrhotic portal hypertension: A new start from the Baveno Ⅶ consensus
Xiaofeng ZHANG, Jinjun CHEN
2022, 38(6): 1217-1219. DOI: 10.3969/j.issn.1001-5256.2022.06.001
Abstract(1251) HTML (305) PDF (1911KB)(302)
Abstract:
The new consensus on portal hypertension issued by Baveno Cooperative Group, i.e., the Baveno Ⅶ consensus, summarizes the diagnostic criteria for portal hypertension, noninvasive screening and diagnosis, primary prevention including etiological treatment and non-etiological treatment, secondary prev...
Discussions by Experts
Noninvasive screening and management of cirrhotic portal hypertension
Xiaofeng ZHANG, Jinjun CHEN
2022, 38(6): 1220-1223. DOI: 10.3969/j.issn.1001-5256.2022.06.002
Abstract(950) HTML (223) PDF (1854KB)(170)
Abstract:
Portal hypertension-related complications are the major cause of death in patients with advanced chronic liver disease (ACLD). Hepatic venous pressure gradient is the golden standard for assessing portal hypertension, and upper gastrointestinal endoscopy is an important method for screening and asse...
Etiological and non-etiological therapies for cirrhotic portal hypertension
Yuerong LI, Min WANG, Fuliang He, Xinyan ZHAO, Xiaojuan OU, Hong YOU, Jidong JIA, Yu WANG
2022, 38(6): 1224-1228. DOI: 10.3969/j.issn.1001-5256.2022.06.003
Abstract(836) HTML (228) PDF (1861KB)(231)
Abstract:
Portal hypertension is a serious complication of liver cirrhosis resulting from the increases in portal vascular resistance and portal blood inflow. Both etiological and non-etiological therapies can effectively reduce portal venous pressure to a certain degree, but with an unsatisfactory effect in ...
Application status and future prospect of transjugular intrahepatic portosystemic shunt in gastroesophageal variceal bleeding in liver cirrhosis
Yong LYU, Daiming FAN, Guohong HAN
2022, 38(6): 1229-1233. DOI: 10.3969/j.issn.1001-5256.2022.06.004
Abstract(908) HTML (242) PDF (1869KB)(204)
Abstract:
Gastroesophageal variceal bleeding is the life-threating complication of cirrhotic portal hypertension, and transjugular intrahepatic portosystemic shunt (TIPS) is an effective therapy for portal hypertension-related complications. TIPS can be used for the prevention of first-time bleeding in patien...
Anticoagulant therapy and transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid related hepatic sinusoidal obstruction syndrome
Wei ZHANG, Yuzheng ZHUGE
2022, 38(6): 1234-1236. DOI: 10.3969/j.issn.1001-5256.2022.06.005
Abstract(947) HTML (178) PDF (1831KB)(123)
Abstract:
Hepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease characterized by varying degrees of liver injury and portal hypertension. HSOS in China is mostly associated with the intake of pyrrolizidine alkaloids. The step-up approach with anticoagulant therapy and transjugular intrahe...
Portal hypertensive enteropathy: A disease that should not be ignored among the complications of portal hypertension
Shanshan LI, Changqing YANG
2022, 38(6): 1237-1241. DOI: 10.3969/j.issn.1001-5256.2022.06.006
Abstract(1123) HTML (285) PDF (2807KB)(187)
Abstract:
Although portal hypertensive enteropathy (PHE) is similar to portal hypertensive gastroenteropathy, it has various endoscopic manifestations with a lack of specificity, and there are still no unified diagnostic criteria. It is easily ignored by clinicians due to great individual differences and the ...
Guidelines
Clinical practice guidelines for the interventional treatment of advanced pancreatic carcinoma (on trial) (6th edition)
2022, 38(6): 1242-1251. DOI: 10.3969/j.issn.1001-5256.2022.06.007
Abstract(1335) HTML (282) PDF (2941KB)(249)
Abstract:
An excerpt of EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis(2022)
Yuhang YIN, Wentao XU, Fuliang HE, Xingshun QI
2022, 38(6): 1252-1255. DOI: 10.3969/j.issn.1001-5256.2022.06.008
Abstract(995) HTML (205) PDF (1829KB)(228)
Abstract:
An excerpt of investigation and management of Wilson's disease: A practical guide from the British Association for the Study of the Liver (2022)
Weiyuan FANG, Jianshe WANG
2022, 38(6): 1256-1257. DOI: 10.3969/j.issn.1001-5256.2022.06.009
Abstract(778) HTML (187) PDF (1812KB)(138)
Abstract:
An excerpt of report of the Baveno Ⅶ Consensus Workshop: Personalized care in portal hypertension
Xiaofeng ZHANG, Qinjun HE, Haiyu WANG, Jiankang SONG, Yuanjian ZHANG, Miaoxia LIU, Yali JI, Jinjun CHEN
2022, 38(6): 1258-1268. DOI: 10.3969/j.issn.1001-5256.2022.06.010
Abstract(1052) HTML (456) PDF (1926KB)(320)
Abstract:
Original Articles_Viral Hepatitis
Effect of the change in antiviral therapy indication in increasing the treatment rate of chronic hepatitis B
Hao WANG, Shan SHAN, Hong YOU, Xiaoyuan XU, Lai WEI, Jinlin HOU, Hui ZHUANG, Yuanyuan KONG, Jidong JIA, China Registry of Hepatitis B (CR-HepB) Group
2022, 38(6): 1269-1274. DOI: 10.3969/j.issn.1001-5256.2022.06.011
Abstract(992) HTML (190) PDF (2465KB)(167)
Abstract:
Objective To investigate the impact of the change in anti-hepatitis B virus (HBV) therapy indication on treatment rate and the features of the population requiring treatment. Methods The treatment-naïve patients with chronic hepatitis B (CHB) in the China Registry of Hepatitis B (CR-HepB) database w...
Influence of copy number variations in the FCGR3A and FCGR3B genes on the outcome of hepatitis B virus infection
Haotian LI, Tongtong WANG, Xutong LI, Yufeng GAO
2022, 38(6): 1275-1279. DOI: 10.3969/j.issn.1001-5256.2022.06.012
Abstract(460) HTML (277) PDF (1867KB)(46)
Abstract:
Objective To investigate the association of copy number variations (CNVs) in the FCGR3A and FCGR3B genes with different outcomes and disease progression after hepatitis B virus (HBV) infection. Methods Peripheral blood samples were collected from 841 patients with chronic HBV infection and 296 patie...
Effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing
Yixin HOU, Qun ZHANG, Yuyong JIANG, Hao YU, Yuying YANG, Xianbo WANG
2022, 38(6): 1280-1287. DOI: 10.3969/j.issn.1001-5256.2022.06.013
Abstract(582) HTML (178) PDF (5458KB)(33)
Abstract:
Objective To investigate the effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Methods The patients who were hospitalized and diagnosed with HBV-ACLF in Beijing Ditan Hospital from October 2018 to October 2019...
Original Articles_Fatty Liver Diseases
Diagnostic accuracy of FibroScan-AST score in nonalcoholic steatohepatitis with significant activity and fibrosis
Gangde ZHAO, Simin GUO, Qing XIE, Honglian GUI
2022, 38(6): 1288-1292. DOI: 10.3969/j.issn.1001-5256.2022.06.014
Abstract(1263) HTML (432) PDF (1857KB)(136)
Abstract:
Objective To investigate the diagnostic accuracy of FibroScan-AST (FAST) score in patients with high-risk nonalcoholic steatohepatitis (NASH) with a nonalcoholic fatty liver disease (NAFLD) activity score of ≥4 and significant liver fibrosis (F ≥2), along with comparison with other serological model...
Influence of vitamin D deficiency on fibrosis-4 index and disease severity in patients with nonalcoholic steatohepatitis
Quan ZHOU, Jinqiang LI, Xiaowu LI
2022, 38(6): 1293-1298. DOI: 10.3969/j.issn.1001-5256.2022.06.015
Abstract(725) HTML (342) PDF (2576KB)(64)
Abstract:
Objective To investigate the influence of vitamin D deficiency on nonalcoholic steatohepatitis (NASH). Methods The patients with NASH who were hospitalized in Department of Infectious Diseases, The First Hospital of Changsha, from January 2020 to October 2021 were enrolled, and according to the seru...
Clinical significance of the determination of fecal short-chain fatty acids in patients with nonalcoholic fatty liver disease
Hui LI, Xuehong WANG, Zhenqi MA, Wenxia MA, Liping YANG
2022, 38(6): 1299-1306. DOI: 10.3969/j.issn.1001-5256.2022.06.016
Abstract(1022) HTML (403) PDF (2410KB)(79)
Abstract:
Objective To investigate the association of the metabolism of intestinal short-chain fatty acids (SCFAs) with the development and progression of the disease spectrum of nonalcoholic fatty liver disease (NAFLD) by determining the content of fecal SCFAs in patients with different NAFLD diseases and th...
Original Articles_Autoimmune Liver Diseases
Value of serum IgG4 level in differential diagnosis of IgG4-related pancreatic and hepatobiliary diseases and non-IgG4-related pancreatic and hepatobiliary diseases
Chang LI, Lei YAN, Li WANG, Chongxu HAN, Yunfeng YE, Defu JIN, Yuzhang JIANG
2022, 38(6): 1307-1310. DOI: 10.3969/j.issn.1001-5256.2022.06.017
Abstract(644) HTML (156) PDF (1986KB)(50)
Abstract:
Objective To investigate the value of serum IgG4 level in the differential diagnosis of IgG4-related pancreatic and hepatobiliary disease (IgG4-PHD) and non-IgG4-related disease (non-IgG4-RD). Methods Clinical data were collected from 491 patients who were hospitalized and 50 individuals who underwe...
Original Articles_Liver Fibrosis and Liver Cirrhosis
Association of energy metabolic markers with the short-term risk of spontaneous bacterial peritonitis in patients with decompensated hepatitis B virus-related liver cirrhosis
Xiumin CHEN, Shenglong LIN, Xiangmei WANG, Huaxi MA, Dongqing ZHANG, Ziyuan LIAO, Minghua LIN, Haibing GAO
2022, 38(6): 1311-1316. DOI: 10.3969/j.issn.1001-5256.2022.06.018
Abstract(611) HTML (143) PDF (2128KB)(48)
Abstract:
Objective To investigate the association of energy metabolic markers with the risk of spontaneous bacterial peritonitis (SBP) in patients with decompensated hepatitis B virus-related liver cirrhosis (HBV-LC). Methods A retrospective analysis was performed for the clinical data of the patients with d...
Original Articles_Liver Neoplasms
Value of multi-glycan in the auxiliary diagnosis of dual-phenotype hepatocellular carcinoma
Huijuan FENG, Yu ZHANG, Chuanshang ZHUO, Chenjun HUANG, Meng FANG, Lijuan LIU
2022, 38(6): 1317-1322. DOI: 10.3969/j.issn.1001-5256.2022.06.019
Abstract(541) HTML (320) PDF (3387KB)(35)
Abstract:
Objective To investigate the expression of multi-glycan in serum of patients with dual-phenotype hepatocellular (DPHCC) and its clinical significance. Methods Serum samples were collected from 65 patients with DPHCC, 80 patients with primary hepatocellular carcinoma (HCC), and 120 patients with live...
Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor
Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN
2022, 38(6): 1323-1327. DOI: 10.3969/j.issn.1001-5256.2022.06.020
Abstract(865) HTML (273) PDF (2021KB)(48)
Abstract:
Objective To investigate the efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) previously treated with tyrosine kinase inhibitor (TKI). Methods A retrospective analysis was performed for the clinical data of 76 patients with unresectable HCC who were trea...
Expression of calcitonin gene-related peptide-receptor component protein in hepatocellular carcinoma and its association with prognosis
Guanqun SUN, Silei ZHOU, Tanlun ZENG, Junyu LIU, Xijun LIANG, Zhuo CHENG
2022, 38(6): 1328-1333. DOI: 10.3969/j.issn.1001-5256.2022.06.021
Abstract(861) HTML (428) PDF (3225KB)(50)
Abstract:
Objective To investigate the expression level of calcitonin gene-related peptide-receptor component protein (CRCP) in hepatocellular carcinoma (HCC) tissue and adjacent tissue and its association with the clinicopathological features and prognosis of patients. Methods HCC and adjacent tissue samples...
Original Articles_Other Liver Diseases
Influencing factors for the prognosis of biopsy proven patients with chronic drug-induced liver injury: An analysis of 255 cases
Qiaoling WANG, Qingsheng LIANG, Ang HUANG, Xingran ZHAI, Huang XIE, Ying SUN, Zhengsheng ZOU
2022, 38(6): 1334-1340. DOI: 10.3969/j.issn.1001-5256.2022.06.022
Abstract(760) HTML (176) PDF (3674KB)(71)
Abstract:
Objective To investigate the influencing factors for the prognosis of adult patients with chronic drug-induced liver injury (DILI). Methods A total of 255 patients who were diagnosed with chronic DILI by liver biopsy in The Fifth Medical Center of Chinese PLA General Hospital from January 2014 to De...
Inhibitory effect of lidocaine on Kupffer cell inflammatory response and its effect on liver abscess formation in diabetic mice
Ruibin WANG, Yuzheng LU, Jinglin ZHU, Wei WANG, Guang JIA
2022, 38(6): 1341-1346. DOI: 10.3969/j.issn.1001-5256.2022.06.023
Abstract(580) HTML (276) PDF (3726KB)(39)
Abstract:
Objective To investigate whether lidocaine can reverse Kupffer cell dysfunction in diabetic mice, as well as the mechanism of lidocaine in affecting liver abscess formation by improving the phagocytic function of Kupffer cells. Methods C57BLKS/J db/db mice were divided into diabetes control group an...
Original Articles_Biliary Diseases
Etiological characteristics of infection after percutaneous biliary drainage or stent implantation for malignant biliary obstruction
Siyin LI, Zhi LI, Bingke JIAO, Qiyuan HONG, Xiaoqing JIANG, Jianwei ZOU, Caifang NI
2022, 38(6): 1347-1350. DOI: 10.3969/j.issn.1001-5256.2022.06.024
Abstract(544) HTML (168) PDF (2071KB)(43)
Abstract:
Objective To investigate the etiological characteristics of infection after percutaneous biliary drainage or stent implantation in patients with malignant biliary obstruction (MBO). Methods Clinical data were collected from MBO patients who underwent interventional therapy in Department of Intervent...
Original Articles_Pancreatic Diseases
Ultrasound findings and contrast-enhanced ultrasound findings of mass-type autoimmune pancreatitis versus pancreatic ductal adenocarcinoma
Xiangliu OUYANG, Yunxia HAN, Lichun ZHENG, Yingchun ZHAO, Xinyu SHEN, Wenjun ZHANG, Yanbin WANG
2022, 38(6): 1351-1355. DOI: 10.3969/j.issn.1001-5256.2022.06.025
Abstract(804) HTML (355) PDF (3738KB)(30)
Abstract:
Objective To investigate the value of ultrasound and contrast-enhanced ultrasound (CEUS) in the differential diagnosis of mass-type autoimmune pancreatitis (AIP) and pancreatic ductal adenocarcinoma (PDAC). Methods A retrospective analysis was performed for the clinical data, ultrasound findings, an...
Efficacy and safety of enhanced recovery after surgery in the perioperative period of pancreaticoduodenectomy: A systematic review and Meta-analysis
Lin ZHU, Xiaoli YANG, Li LIU, Lanting XU, Yuanhong LENG, Jing CHEN
2022, 38(6): 1356-1363. DOI: 10.3969/j.issn.1001-5256.2022.06.026
Abstract(788) HTML (211) PDF (3967KB)(47)
Abstract:
Objective To investigate the efficacy and safety of enhanced recovery after surgery (ERAS) in the perioperative period of pancreaticoduodenectomy (PD). Methods Chinese and English databases were searched for controlled clinical trials on the application of ERAS in PD published from 2000 to 2021. Scr...
Case Reports
Toxic epidermal necrolysis related to entecavir: A case report and literature review
Rui LU, Xiaozhen GENG, Shuangsuo DANG, Wenjun WANG
2022, 38(6): 1364-1366. DOI: 10.3969/j.issn.1001-5256.2022.06.027
Abstract(670) HTML (159) PDF (1832KB)(62)
Abstract:
Hepatitis B cirrhosis with hepatic paragonimiasis misdiagnosed as primary liver cancer: A case report
Shenfeng HUANG, Jiajun LIN, Yang TAN, Zhifang CAI
2022, 38(6): 1367-1369. DOI: 10.3969/j.issn.1001-5256.2022.06.028
Abstract(552) HTML (138) PDF (2412KB)(38)
Abstract:
Giant focal nodular hyperplasia of the liver in children: A case report
Cheng CHEN, Junjie WANG, Yakun WU
2022, 38(6): 1370-1372. DOI: 10.3969/j.issn.1001-5256.2022.06.029
Abstract(632) HTML (181) PDF (3134KB)(49)
Abstract:
Carcinosarcoma of the liver: A case report
Liang CHEN, Jincai WU, Jiacheng CHEN, Xiangxiang LUO, Rong TANG, Hande QIN, Kailun ZHOU
2022, 38(6): 1373-1374. DOI: 10.3969/j.issn.1001-5256.2022.06.030
Abstract(673) HTML (96) PDF (3285KB)(45)
Abstract:
Brain abscess secondary to liver abscess in type 2 diabetes mellitus: A case report
Deyun WANG, Ruirui JIN, Zhen ZHAO, Hui LI
2022, 38(6): 1375-1376. DOI: 10.3969/j.issn.1001-5256.2022.06.031
Abstract(583) HTML (196) PDF (1890KB)(53)
Abstract:
Hepatic alveolar echinococcosis invading the bile ducts and the inferior vena cava: A case report
Hongen LIU, Tingting ZHANG, Zhixin WANG, Xinjian GUO, Haijiu WANG, Haining FAN, Li REN, Lizhao HOU
2022, 38(6): 1377-1379. DOI: 10.3969/j.issn.1001-5256.2022.06.032
Abstract(597) HTML (141) PDF (3744KB)(48)
Abstract:
Clonorchiasis with pleural and peritoneal effusion and dilatation of the intrahepatic and extrahepatic bile ducts: A case report
Qiuting ZENG, Yanfang CHEN, Shaohui TANG
2022, 38(6): 1380-1382. DOI: 10.3969/j.issn.1001-5256.2022.06.033
Abstract(713) HTML (276) PDF (2003KB)(39)
Abstract:
Reviews
Role of N6-methyladenosine methylation in hepatitis B virus infection
Ping XUE, Chao FAN
2022, 38(6): 1383-1386. DOI: 10.3969/j.issn.1001-5256.2022.06.034
Abstract(722) HTML (192) PDF (2985KB)(46)
Abstract:
The phenomenon of N6-methyladenosine (m6A)-methylation is commonly observed in various tissues and cells of the human body and is the most common type of internal modification in eukaryotic mRNA. m6A-methylation is dynamic and reversible, which is regulated by various methyltransferases, demethylase...
Advances in the research and development of new drugs for chronic hepatitis B
Yisi LIU, Xinyue CHEN
2022, 38(6): 1387-1392. DOI: 10.3969/j.issn.1001-5256.2022.06.035
Abstract(1525) HTML (786) PDF (2381KB)(217)
Abstract:
At present, antiviral therapy for chronic hepatitis B (CHB) has a low clinical cure rate and hardly remove cccDNA. With the progress of medical science, more and more new drugs are in the stage of research and development. This article focuses on the research and development of representative drugs ...
Association of signal transducer and activator of transcription 3 and signal transducer and activator of transcription 5 with regulatory T cell/T helper 17 cell balance in chronic hepatitis B
Minyue LI, Hongju YANG, Jing LI, Rui SONG, Jing YOU
2022, 38(6): 1393-1397. DOI: 10.3969/j.issn.1001-5256.2022.06.036
Abstract(626) HTML (152) PDF (2038KB)(33)
Abstract:
The immune mechanism of chronic hepatitis B (CHB) persistent infection is closely associated with T cells, and the development of T cells requires the coordination of a variety of cytokines. The proteins of the signal transducer and activator of transcription (STAT) family are mainly involved in the...
Advances in phase Ⅲ drug studies on the pipeline in nonalcoholic steatohepatitis
Yu WANG, Xuebing YAN
2022, 38(6): 1398-1401. DOI: 10.3969/j.issn.1001-5256.2022.06.037
Abstract(1361) HTML (480) PDF (1860KB)(237)
Abstract:
Nonalcoholic steatohepatitis (NASH) can cause end-stage liver diseases such as liver cirrhosis and liver cancer, and therefore, it is urgent to treat NASH, reverse hepatic steatosis, and delay the onset of end-stage liver diseases. NASH has a complex pathogenesis and there are currently no effective...
Application of farnesoid X receptor agonists in treatment of nonalcoholic steatohepatitis
Zhenyang SHEN, Xiaobo CAI, Lungen LU
2022, 38(6): 1402-1405. DOI: 10.3969/j.issn.1001-5256.2022.06.038
Abstract(835) HTML (163) PDF (1851KB)(116)
Abstract:
Nonalcoholic steatohepatitis (NASH) is a liver disease with a relatively high prevalence worldwide and greatly threatens human health. In recent years, farnesoid X receptor-related drugs have played an important role in regulating the metabolism of bile acid, glucose, and lipids and inhibiting infla...
Association of glucagon-like peptide-1 system with the prevention and treatment of nonalcoholic fatty liver disease
Hongliang CUI, Li XU, Tong LU
2022, 38(6): 1406-1410. DOI: 10.3969/j.issn.1001-5256.2022.06.039
Abstract(668) HTML (363) PDF (2126KB)(41)
Abstract:
With a large number of patients, nonalcoholic fatty liver disease (NAFLD) has become one of the major chronic liver diseases that jeopardize the health of people worldwide. This article introduces the major factors in glucagon-like peptide-1 (GLP-1) system that are associated with the production, de...
Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease
Qingling ZHONG, Liangping LI
2022, 38(6): 1411-1415. DOI: 10.3969/j.issn.1001-5256.2022.06.040
Abstract(1800) HTML (727) PDF (2304KB)(167)
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a manifestation of multi-system dysfunction involving the liver, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. An increasing number of studies have shown the importance...
Production mechanism and detection value of anti-gp210 antibody in primary biliary cholangitis
Jihong ZHANG, Suling LI
2022, 38(6): 1416-1419. DOI: 10.3969/j.issn.1001-5256.2022.06.041
Abstract(916) HTML (585) PDF (1852KB)(66)
Abstract:
Primary biliary cholangitis (PBC) is one of the autoimmune liver diseases, and most patients have no obvious clinical manifestations in the early stage and have reached the advanced stage when symptoms appear. Therefore, it is necessary to make a confirmed diagnosis and evaluate prognosis as early a...
Regulation of liver fibrosis by matrix metalloproteinase/tissue inhibitor of metalloproteinase and research advances in related therapeutic drugs
Qian HUANG, Yan YANG, Rui ZENG, Menglin YAO, Qin SUN
2022, 38(6): 1420-1425. DOI: 10.3969/j.issn.1001-5256.2022.06.042
Abstract(1457) HTML (217) PDF (2286KB)(148)
Abstract:
Liver fibrosis is the common consequence of various chronic liver injuries and is mainly characterized by the imbalance between the production and degradation of extracellular matrix, which leads to the accumulation of interstitial collagen and other matrix components. Matrix metalloproteinases (MMP...
Role of platelets in the development and progression of hepatocellular carcinoma
Xiao YU, Guobing WU, Aibin ZHANG, Xiaolong CHENG, Min LIU, Zenan HU, Ya ZHENG, Yuping WANG, Zhaofeng CHEN
2022, 38(6): 1426-1430. DOI: 10.3969/j.issn.1001-5256.2022.06.043
Abstract(955) HTML (560) PDF (3360KB)(177)
Abstract:
Hepatocellular carcinoma is one of the common causes of tumor-related death, and it has high morbidity and mortality rates in China. Recent studies have shown that platelets are closely associated with the development of hepatocellular carcinoma. Literature review shows that platelets not only parti...
Research advances in autoimmune hepatitis-related hepatocellular carcinoma
Wenpei GUO, Haiyan ZHANG, Lixin LIU
2022, 38(6): 1431-1435. DOI: 10.3969/j.issn.1001-5256.2022.06.044
Abstract(784) HTML (257) PDF (1859KB)(81)
Abstract:
Autoimmune hepatitis (AIH)-related hepatocellular carcinoma (HCC) is defined as HCC that develops on the basis of long-term AIH and has a relatively low incidence rate of 0-6%. The risk factors for HCC in AIH patients include old age, male sex, diabetes, alcohol use, AIH recurrence and persistent al...
Association between mitochondrial dysfunction and hepatocellular carcinoma
Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU
2022, 38(6): 1436-1439. DOI: 10.3969/j.issn.1001-5256.2022.06.045
Abstract(1185) HTML (361) PDF (2104KB)(113)
Abstract:
Hepatocellular carcinoma (HCC) is a type of tumor with a high incidence rate, a low rate of early diagnosis, and poor prognosis, and its development and progression involve many factors. As an important organelle in cells, mitochondria is the "energy factory" of cells and is one of the main sites fo...
Indoleamine 2, 3-dioxygenase: An important medium with the role of a double-edged sword in various liver diseases
Sen YE, Hongbin WANG, Yong FU
2022, 38(6): 1440-1444. DOI: 10.3969/j.issn.1001-5256.2022.06.046
Abstract(671) HTML (182) PDF (1905KB)(25)
Abstract:
Indoleamine 2, 3-dioxygenase (IDO) is an important immunoregulatory enzyme, which can degrade the level of the mammalian essential amino acid tryptophan (TRP), catalyze the initiation and rate-limiting steps through the kynurenine pathway, and produce a variety of metabolites to participate in the i...
Research advances in endoscopic interventional treatment of acute cholecystitis
Siying LIU, Peng LI, Shutian ZHANG, Fujing LYU
2022, 38(6): 1445-1448. DOI: 10.3969/j.issn.1001-5256.2022.06.047
Abstract(742) HTML (461) PDF (1843KB)(62)
Abstract:
Acute cholecystitis is a common acute abdominal disease, and it can be classified into grade Ⅰ (mild), grade Ⅱ (moderate), and grade Ⅲ (severe) based on severity. Gallbladder drainage is an important treatment method for patients with severe disease conditions and a high surgical risk. Percutaneous ...
Introduction of High-quality Articles in Foreign Journals
Hepatology Research｜Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients
2022, 38(6): 1228-1228. DOI: 10.3969/j.issn.1001-5256.2022.06.gwjpwzjj1
Abstract(290) HTML (130) PDF (851KB)(54)
Abstract:
Hepatology Communications｜Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing
2022, 38(6): 1369-1369. DOI: 10.3969/j.issn.1001-5256.2022.06.gwjpwzjj2
Abstract(886) HTML (225) PDF (850KB)(28)
Abstract:
Hepatology｜HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage
2022, 38(6): 1382-1382. DOI: 10.3969/j.issn.1001-5256.2022.06.gwjpwzjj3
Abstract(356) HTML (134) PDF (853KB)(30)
Abstract:
Thanks
Current reviewers
2022, 38(6): 1448-1448. DOI: 10.3969/j.issn.1001-5256.2022.6.zhixie1
Abstract(272) HTML (143) PDF (844KB)(32)
Abstract:
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2433]YesterdayPV[3993]TodayIP[2044]TodayPV[3293]Online[91]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd